Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.580
+0.170 (3.85%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Arbutus Biopharma Employees
Arbutus Biopharma had 19 employees as of December 31, 2025. The number of employees decreased by 25 or -56.82% compared to the previous year.
Employees
19
Change (1Y)
-25
Growth (1Y)
-56.82%
Revenue / Employee
$10,076,053
Profits / Employee
$8,458,947
Market Cap
904.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 19 | -25 | -56.82% | 19 | 0 |
| Dec 31, 2024 | 44 | -29 | -39.73% | 44 | 0 |
| Dec 31, 2023 | 73 | -25 | -25.51% | 73 | 0 |
| Dec 31, 2022 | 98 | 11 | 12.64% | 96 | 2 |
| Dec 31, 2021 | 87 | 9 | 11.54% | 85 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| Solid Biosciences | 121 |
| Janux Therapeutics | 108 |
| Odyssey Therapeutics | 100 |
| Annexon | 93 |
| Theravance Biopharma | 90 |
| Vor Biopharma | 76 |
| Alto Neuroscience | 68 |
ABUS News
- 6 weeks ago - Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Arbutus Biopharma Quarterly report: Q1 2026 - Filings
- 6 weeks ago - Arbutus Biopharma Earnings release: Q1 2026 - Filings
- 2 months ago - Arbutus Biopharma granted Fast Track designation for imdusiran - TheFly
- 2 months ago - Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B - GlobeNewsWire
- 2 months ago - Arbutus Biopharma Proxy statement: Proxy filing - Filings
- 2 months ago - Arbutus Biopharma Proxy statement: Proxy filing - Filings
- 2 months ago - Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies - TheFly